



SWISS BRIDGE  
INVEST IN CANCER RESEARCH WORLDWIDE



NEWSLETTER  
CHRISTMAS 2023



SPECIAL EDITION  
SWISS BRIDGE AWARD 2023

Zurich, December 2023

## Resistance To Cancer Therapies

Half a Million Swiss Francs for two research projects



Philipp Lücke (CEO), Prof. Dr. Lukas Flatz, Prof. Dr. Jakob Passweg (President),  
Prof. Dr. Adrian Ochsenbein (Chairman Scientific Jury)

Zurich, 24 October 2023 – **Two research scientists from Austria and Switzerland will receive the SWISS BRIDGE Award 2023.** The award sum of 250'000 Swiss francs each is intended to contribute to a better understanding of the development of therapy resistance in cancer and to find new treatment methods.

Most cancer patients initially respond well to their therapies. Over time, however, resistance to these therapies can develop, causing the treatments to stop working. As a result, the cancer becomes uncontrollable, and the cancer can continue to spread throughout the body. The exact causes and how such therapy resistance develops are not yet sufficiently understood.

For this reason, the SWISS BRIDGE foundation has dedicated this year's award to this topic. A total of 70 young scientists from all over Europe applied for the award this year. In a two-stage evaluation process, a scientific jury of distinguished experts gave priority to two research projects. The investigators, **Anna Christina Obenauf** from the Research Institute of Molecular Pathology in Vienna and **Lukas Flatz** from the Cantonal Hospital in St. Gallen, will each receive 250'000 Swiss francs to be invested in the realization of their research projects.



CHRISTMAS 2023



## Lukas Flatz

(MD)

Institute of Immunobiology  
Kantonsspital St. Gallen  
Rorschacherstrasse 95  
9007 St. Gallen  
Switzerland


Project title:

## Discover markers of resistance in skin cancer

**Lukas Flatz** and his research group study skin cancers such as squamous cell carcinoma and melanoma. For these cancers, too, a new form of therapy known as immune checkpoint inhibitors has revolutionized treatment in recent years. But here, too, the development of resistance poses a major challenge in treatment.

Lukas Flatz and his team have found evidence that a process called tumor differentiation may be responsible for this resistance. In this process, cancer cells lose their specialized properties and become more primitive. This can lead to them being less well recognized and fought by the body's immune defenses and allowing them to spread to other parts of the body.

„We believe that the de-differentiation of cancer cells is caused by a process called immune editing, in which the immune system puts pressure on the tumors and changes their properties,“ says Lukas Flatz. In the project, he and his team want to discover markers for de-differentiation in melanoma and squamous cell carcinoma. This could significantly improve the diagnosis of these cancers and open up new treatment options.



WANT TO SUPPORT  
THIS PROJECT?  
WE LOOK FORWARD TO HEARING FROM YOU.



WARD  
23



Project title:

## Fighting resistant cells

**Anna Christina Obenauf**  
(PhD)

Research Institute  
of Molecular Pathology (IMP)  
Campus-Vienna-Biocenter 1  
1030 Vienna  
Austria



**Anna Christina Obenauf** and her team are studying treatment resistance in lung cancer. About 20 to 25 percent of lung cancer cases have mutations in a gene called KRAS. If these mutations are present, novel targeted therapies have been available for treatment for several years.

Although these novel therapies initially achieve impressive results, most patients cannot be cured due to the emergence of resistance. The award-winning project aims to study a specific type of cancer cells that can survive therapeutic treatment and eventually become insensitive to the therapy, known as persister cells. **„We want to understand why these cells survive and develop resistance, and then find ways to stop them before they become a problem,“** says **Anna Christina Obenauf**. To do this, they use cutting-edge technologies that allow them to track the behavior and molecular evolution of individual cancer cells.

In the context of new targeted KRAS therapies, they thus hope to discover weak points in the persister cells that can be attacked in combination with other therapies.



WANT TO SUPPORT  
THIS PROJECT?  
WE LOOK FORWARD TO HEARING FROM YOU.





## GOLF EVENT 2023

Golf Club Sagogn, 23st August 2023

It was another glorious day of golf and a wonderful evening. Many thanks to everyone who turned up to the loyal sponsors and friends of SWISS BRIDGE for their great support of this event.



## SAVE THE DATE:

SWISS BRIDGE GOLF EVENT 2024



27th August 2024 · Golfclub Lenzerheide



## WHY SWISS BRIDGE

What sets us apart from the rest in the field of cancer research? It is the extremely positive feedback we continuously receive from all our partners:



Distinguished reputation of the SWISS BRIDGE Award



Identification of specific projects in Switzerland and in other countries



Professional scientific jury



Designated donations are made available in full to screened and selected cancer researches & projects



Low cost for advertising, PR, IT and fees, covered by supporters & friends of the foundation



This unique concept enables us to look to the future with optimism and take another important step in the fight against cancer!

**Donations: Credit Suisse · 8070 Zurich · IBAN: CH52 0483 5095 7385 1100 0**

## ORGANIZATION

### Board of Foundation

Prof. Dr. Jakob Passweg  
(Chairman)  
Eleonore E. Droux, Herrliberg  
Dr. Thomas Peter, Küsnacht  
Yves Monnard, Zurich  
Liv Bahner, Zurich

### Scientific Jury

Prof. Dr. Adrian Ochsenbein  
(Chairman)

### Honory Chairman

Prof. Dr. Giorgio Nosedà

### Management

Philipp Lücke (CEO)

### Board of Patrons

Dr. med. Jaques Bernier, Geneva  
Prof. Dr. med. Dr. h.c. Urs Metzger, Zurich  
Sir Paul Nurse, London  
Heinz Roth, Uitikon/ Waldegg  
Prof. Dr. med. Thomas Szucs, Zollikon

### Administration

SWISS BRIDGE Foundation  
P.O. Box 1556, 8027 Zurich  
Phone + 41 (0) 43 31 71 360  
info@swissbridge.ch



[www.swissbridge.ch](http://www.swissbridge.ch)

